Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000980 | 0.86 | GAA (0.68) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL11853033 | 0.86 | GAA (0.68) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL2068967 | 0.85 | KMT2A (0.53) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL34558 | 0.84 | HTR6 (0.77) | HTR6GAAKMT2AALDH1A1CA12 | |
| SCHEMBL395274 | 0.84 | HTR6 (1.00) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL30751995 | 0.84 | HTR6 (1.00) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL9464499 | 0.81 | HTR6 (0.71) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL20723646 | 0.81 | HTR6 (0.71) | HTR6GAAALDH1A1KDM4ECA12 | |
| SCHEMBL9818407 | 0.81 | GAA (0.56) | HTR6GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL14060214 | 0.81 | CA2 (0.57) | HTR6GAAKMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352921-A1 | ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS | CALYGENE BIOTECHNOLGY INC (US) | 2020-11-12 | — | — | US | disclosed |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | BAYLOR COLLEGE OF MEDICINE | 2018-10-11 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9713613-B2 | Methods and compositions for the treatment of cancer and related hyperproliferative disorders | BAYLOR COLLEGE OF MEDICINE | 2017-07-25 | — | — | US | disclosed |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-12 | — | — | US | disclosed |
| US-9233941-B2 | Methods and compositions for the treatment of body weight related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-01-12 | — | — | US | disclosed |
| US-9212179-B2 | Compositions and methods for the treatment of metabolic disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-12-15 | — | — | US | disclosed |
| US-5120872-A | Textile dyeing | CIBA-GEIGY CORPORATION (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0241414-B1 | PROCESS FOR THE PREPARATION OF 1:2 METAL COMPLEX AZO DYES | CIBA-GEIGY AG (CH) | 1991-05-08 | — | — | EP | disclosed |
| US-4997921-A | Substituted phenylazosulfoindole dyes | CIBA-GEIGY CORPORATION (US) | 1991-03-05 | — | — | US | disclosed |
| US-4994563-A | Dyeing, printing cellulose, silk, wool, synthetic polyamides; colorfastness | CIBA-GEIGY CORPORATION (US) | 1991-02-19 | — | — | US | disclosed |
| US-4954563-A | Polyamide dye | CIBA-GEIGY CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0349486-A2 | Azo dyes, their preparation and their use | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | disclosed |
| EP-0121495-B1 | MONOAZO DYESTUFFS, THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1986-12-17 | — | — | EP | disclosed |
| EP-0121495-A1 | Monoazo dyestuffs, their preparation and their use | CIBA-GEIGY AG (CH) | 1984-10-10 | — | — | EP | disclosed |
| US-4370431-A | Process for coloring fibre forming polyamides in the melt with azo pigments | CIBA-GEIGY CORPORATION (US) | 1983-01-25 | — | — | US | disclosed |
| EP-0046729-A2 | Process for the mass colouring of polyamide fibres with azo dyestuffs | CIBA-GEIGY AG (CH) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | HTR6 3886/4885GAA 1272/4885KMT2A 1916/4885 |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | ABAT, CPT1B, LRBA | HTR6 1706/4885GAA 353/4885KMT2A 1855/4885 |
| US-20200352921-A1 | ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS | TRPM6, TRPM2, TRPM5 | HTR6 1250/4885GAA 42/4885KMT2A 1258/4885 |
| US-20180291013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND RELATED DISORDERS | FABP4, LIPC, PNLIP | HTR6 2469/4885GAA 165/4885KMT2A 1731/4885 |
| US-20160257675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | HTR6 2722/4885GAA 149/4885KMT2A 1970/4885 |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | HCCS, PCNA, MKI67 | HTR6 3877/4885GAA 1310/4885KMT2A 1884/4885 |
| US-20160221999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | FABP4, LIPC, FABP1 | HTR6 2722/4885GAA 149/4885KMT2A 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.